On Wednesday, Following U.S. Stocks were among the “Top Losers”: Vera Bradley, (NASDAQ:VRA), Memorial Resource Development, (NASDAQ:MRD), Emerald Oil, (NYSEMKT:EOX), CorMedix, (NYSEMKT:CRMD)

Vera Bradley, (NASDAQ:VRA), with shares dwindled -16.21%, closed at $15.14, hitting new 52-week low of $14.81.

Emerald Oil, (NYSEMKT:EOX), with shares declined -14.94%, settled at $0.91.

Memorial Resource Development, (NASDAQ:MRD), with shares dipped -14.92%, and closed at $17.45.

CorMedix, (NYSEMKT:CRMD), dropped -11.91%, and closed at $8.06.

Latest NEWS regarding these Stocks are depicted underneath:

Vera Bradley, Inc. (NASDAQ:VRA)

Vera Bradley, Inc. (VRA), declared its financial results for the fourth quarter and fiscal year ended January 31, 2015.

Summary of Financial Performance:

Net proceeds from ongoing operations totaled $152.6 million for the current year fourth quarter ended January 31, 2015, contrast to $156.4 million in the preceding year fourth quarter ended February 1, 2014.

For the current year fourth quarter, the Corporation recorded net revenue from ongoing operations of $17.3 million, or $0.43 per diluted share. Those results comprised of a net after-tax benefit of $0.2 million comprised of:

• $1.9 million of charges related to the planned closing of its Indiana manufacturing facility, primarily related to raw materials inventory write downs;
• a $0.9 million benefit for gift card “breakage” (gift cards that consumers have failed to redeem); and
• a $1.2 million revenue tax benefit related to the Corporation exiting its direct business in Japan.

In the preceding year fourth quarter ended February 1, 2014, revenue from ongoing operations totaled $19.9 million, or $0.49 per diluted share. These results comprised of an after-tax inventory write-down of $3.0 million, or $0.07 per share.

Net proceeds from ongoing operations totaled $509.0 million for fiscal 2015, contrast to $530.9 million for the fiscal year ended February 1, 2014 (“fiscal 2014″). Net revenue from ongoing operations totaled $40.8 million, or $1.00 per diluted share, for fiscal 2015. Those results comprised of the aforementioned net after-tax benefit of $0.2 million. Net revenue from ongoing operations totaled $60.1 million, or $1.48 per diluted share, for fiscal 2014, which comprised of the aforementioned inventory write-down.

Vera Bradley, Inc., through its auxiliaries, designs, produces, markets, and retails functional accessories for women. Its products comprise handbags; totes and specialty bags, counting crossbodies, baby bags, backpacks, and laptop portfolios; technology accessories and fashion accessories, such as wallets, wristlets, eyeglass cases, cosmetics cases, and paper and gift products; and travel and leisure products comprising duffel bags, garment bags, rolling luggage, and travel accessories, such as travel cosmetic cases.

Emerald Oil, Inc. (NYSEMKT:EOX)

Emerald Oil, Inc. (EOX), declared financial and operational results for the quarter and year ended December 31, 2014.

Highlights:

• Raised fourth quarter production to 377,250 BOE, an average of about 4,101 BOEPD, an raise of 7% contrast to the third quarter of 2014 and 71% contrast to the fourth quarter of 2013;
• Raised annual production to 1,295,230 BOE, an average of 3,549 BOEPD, an raise of 110% contrast to 2013;
• Raised total proved reserves to 26.3 MMBOE, an raise of 99% contrast to 2013;
• Raised oil and natural gas sales to $101.2 million in 2014, an raise of 87% contrast to 2013;
• Adjusted EBITDA of $15.0 million or $0.23 per share (basic) for the fourth quarter of 2014 and $56.8 million or $0.85 per share (basic) for 2014, and;
• Adjusted Net Revenue attributable to ordinary shareholders of $2.0 million or $0.03 per share (basic) for the fourth quarter of 2014 and $16.8 million or $0.25 per share (basic) for the year 2014.

Emerald Oil, Inc. operates as an independent oil and natural gas exploration and production corporation in the United States. The corporation designs, drills, and operates oil and natural gas wells. It primarily focuses on acquiring acreage and developing oil and natural gas wells in the Williston Basin located in North Dakota and Montana. As of December 31, 2014, the corporation controlled the rights to mineral leases covering about 122,000 net acres.

Memorial Resource Development Corp. (NASDAQ:MRD)

Memorial Resource Development Corp. (MRD), declared its operating and financial results for the fourth quarter and year ended December 31, 2014.

Fourth Quarter 2014 Results:

Unless otherwise indicated, the operating and financial results talk abouted in this press release only comprise the MRD Segment, which comprises all of MRD’s operations except for Memorial Production Partners LP and its auxiliaries (“MEMP”).

Net production raised 104% year-over-year to 282 MMcfe/d for the fourth quarter 2014 contrast to 139 MMcfe/d for the fourth quarter 2013. Fourth quarter 2014 net production comprised of 225 MMcf/d of natural gas (80%), 6.6 MBbls/d of natural gas liquids (“NGLs”) (14%) and 2.9 MBbls/d of crude oil (6%). In the fourth quarter, about 91% of average daily production was associated with the Terryville Field with the remaining portion attributable to MRD’s East Texas and the Rockies regions. During the fourth quarter 2014, MRD brought online a total of 12 horizontal gross wells, comprising of 11 in the Terryville Field and 1 in East Texas, which was divested in February 2015.

Total proceeds raised 72% to $103.8 million for the fourth quarter 2014 from $60.2 million for the fourth quarter 2013. The raise was primarily due to drilling activity in North Louisiana.

Lease operating expense (“LOE”) for the fourth quarter 2014 was $8.0 million, or $0.31 per Mcfe, contrast to $7.9 million, or $0.62 per Mcfe, for the fourth quarter 2013. The decrease in per unit LOE resulted from raised sales volumes, lower per unit operating cost attributable to pad development and MRD’s continuous efforts to reduce costs.

Production and ad valorem taxes were $3.7 million for the fourth quarter 2014, or $0.14 per Mcfe, contrast to $0.8 million, or $0.06 per Mcfe, for the fourth quarter 2013. Fourth quarter 2014 production and ad valorem taxes raised as compared to fourth quarter 2013 due to higher production and associated proceed.

General and administrative (“G&A”) expense for the fourth quarter 2014 was $12.8 million, or $0.49 per Mcfe, contrast to $16.0 million, or $1.26 per Mcfe, for the fourth quarter 2013. During the fourth quarter 2014, G&A expense comprised of $1.3 million, or $0.05 per Mcfe, of stock-based compensation expense and $0.7 million, or $0.03 per Mcfe, of attainment related costs.

Net interest expense during the fourth quarter 2014 was $5.9 million, counting amortization of deferred financing fees of about $0.7 million. This compares to net interest expense during the fourth quarter 2013 of $11.4 million, counting amortization of deferred financing fees of about $0.8 million. The year-over-year decrease in net interest expense is primarily the result of higher interest rate debt instruments that have since been terminated in addition to $4.5 million of capitalized interest in the fourth quarter 2014.

Capital expenditures totaled $249.5 million in the fourth quarter 2014 and comprised of $96.9 million related to attainments. During the quarter, MRD spent about 97% in the Terryville Field, 2% in East Texas and 1% in the Rockies.

MRD stated Adjusted Net Revenue for the fourth quarter 2014 of $1.8 million contrast to a loss of $1.4 million for the fourth quarter 2013. Adjusted Net Revenue during 2014 was influenced by impairment and exploration expenses related to MRD’s Rockies region.

Memorial Resource Development Corp., an independent natural gas and oil corporation, focuses on the attainment, exploitation, and development of natural gas, natural gas liquids, and oil properties in North Louisiana, in addition to the Rocky Mountains.

CorMedix, Inc. (NYSEMKT:CRMD)

CorMedix, Inc. (CRMD), a pharmaceutical corporation focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, declared that the extension to April 30, 2015 of the expiration date applies to all publicly traded warrants.

The holders of CorMedix warrants should note that the Corporation issued two tranches of warrants in 2010 with the same CUSIP number (No.21900C118). The first tranche of warrants were purchased for cash in connection with the Corporation’s initial public offering of ordinary stock in 2010, and may be exercised at the specified exercise price in exchange for registered, freely tradable shares of ordinary stock issued following a presently effective registration statement.

The second tranche of warrants was also issued in 2010 to a select group of investors in exchange for debt issued preceding to the Corporation’s initial public offering. The holders of these warrants may exercise and receive in exchange shares of unregistered ordinary stock. The Corporation intends to file a registration statement for the resale of the shares issuable upon exercise of the second tranche of warrants as soon as practicable following the filing later this week of the Corporation’s Annual Report Form 10-K.

The exercise date for both tranches of warrants, inclusive of all publicly traded warrants, has been extended from March 24, 2015 to April 30, 2015.

Holders of CorMedix warrants should contact the Corporation’s transfer agent, VStock Transfer, LLC, at the number set forth below for assistance in determining whether their respective warrants were issued in the first or second tranche. Preceding to the availability of the resale registration statement described above, upon exercise holders will not receive shares of ordinary stock free from restrictions on trading unless they can establish that their warrants were originally issued as part of the first tranche.

CorMedix Inc., a development-stage pharmaceutical and medical device corporation, intends to in-license, develop, and commercialize therapeutic products for the treatment of cardiorenal and infectious diseases.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.